HK1179157A1 - Radioimmunoconjugates and uses thereof - Google Patents

Radioimmunoconjugates and uses thereof

Info

Publication number
HK1179157A1
HK1179157A1 HK13106111.6A HK13106111A HK1179157A1 HK 1179157 A1 HK1179157 A1 HK 1179157A1 HK 13106111 A HK13106111 A HK 13106111A HK 1179157 A1 HK1179157 A1 HK 1179157A1
Authority
HK
Hong Kong
Prior art keywords
radioimmunoconjugates
Prior art date
Application number
HK13106111.6A
Other languages
English (en)
Inventor
Roy H Larsen
Jostein Dahle
Oyvind S Bruland
Original Assignee
Nordic Nanovector As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Nanovector As filed Critical Nordic Nanovector As
Publication of HK1179157A1 publication Critical patent/HK1179157A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK13106111.6A 2010-01-29 2013-05-23 Radioimmunoconjugates and uses thereof HK1179157A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29952410P 2010-01-29 2010-01-29
NO20100143A NO331080B1 (no) 2010-01-29 2010-01-29 Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
PCT/EP2011/051231 WO2011092295A2 (en) 2010-01-29 2011-01-28 Novel radioimmunoconjugates and uses thereof

Publications (1)

Publication Number Publication Date
HK1179157A1 true HK1179157A1 (en) 2013-09-27

Family

ID=44319900

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13106111.6A HK1179157A1 (en) 2010-01-29 2013-05-23 Radioimmunoconjugates and uses thereof
HK14109175.2A HK1195736A1 (zh) 2010-01-29 2014-09-11 放射免疫偶聯物和它們的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK14109175.2A HK1195736A1 (zh) 2010-01-29 2014-09-11 放射免疫偶聯物和它們的用途

Country Status (26)

Country Link
US (2) US8628749B2 (zh)
EP (2) EP2528627B1 (zh)
JP (2) JP5646652B2 (zh)
KR (2) KR101893720B1 (zh)
CN (2) CN102762230B (zh)
AU (1) AU2011209441B2 (zh)
BR (1) BR112012018843B8 (zh)
CA (1) CA2786655C (zh)
DK (2) DK2528627T3 (zh)
ES (2) ES2469140T3 (zh)
HK (2) HK1179157A1 (zh)
HR (1) HRP20140538T1 (zh)
IL (2) IL221091A (zh)
MX (2) MX2012008695A (zh)
NO (1) NO331080B1 (zh)
NZ (1) NZ601055A (zh)
PH (1) PH12017501038A1 (zh)
PL (1) PL2528627T3 (zh)
PT (1) PT2528627E (zh)
RS (1) RS53346B (zh)
RU (2) RU2560587C9 (zh)
SG (1) SG182685A1 (zh)
SI (1) SI2528627T1 (zh)
UA (1) UA108631C2 (zh)
WO (1) WO2011092295A2 (zh)
ZA (1) ZA201205007B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX358502B (es) * 2011-12-13 2018-08-23 Nordic Nanovector As Anticuerpo quimerico terapeutico anti-cd37 hh1.
RU2014140119A (ru) * 2012-03-30 2016-05-27 Иммьюноджен, Инк. Способы повышения эффективности терапии на основе cd37
CN103933575B (zh) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
DK3003402T3 (en) * 2013-06-07 2018-04-16 Nordic Nanovector Asa Combination therapy including rituximab and the radiolabelled HH1 monoclonal antibody
UA118198C2 (uk) 2013-08-01 2018-12-10 Ейдженсіс, Інк. Кон'югат антитіло-лікарський засіб, який зв'язується з білком cd37
CA2980462C (en) * 2015-04-07 2023-08-01 The Curators Of The University Of Missouri Nanoparticle immunoconjugates
GB201600328D0 (en) * 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
WO2018050851A1 (en) * 2016-09-16 2018-03-22 Nordic Nanovector Asa Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
KR102406510B1 (ko) 2017-07-03 2022-06-10 현대자동차주식회사 연료전지 시스템용 수소 공급 방법
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
WO2019101789A1 (en) * 2017-11-22 2019-05-31 Nordic Nanovector Asa Radioimmunoconjugates in combination with other drugs as treatment against nhl
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
EP4412715A1 (en) 2021-10-06 2024-08-14 Nordic Nanovector ASA Humanized hh1
CN114081969A (zh) * 2021-11-23 2022-02-25 成都纽瑞特医疗科技股份有限公司 标记的小分子抗体、及其标记方法和应用
CN117285631A (zh) * 2023-11-24 2023-12-26 原子高科股份有限公司 用于放射性免疫治疗的Lu-177标记MUC1抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020009444A1 (en) * 2000-04-25 2002-01-24 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
PL377213A1 (pl) * 2002-12-13 2006-01-23 Mitra Medical Technology Ab Antychłoniakowe środki ukierunkowujące z funkcjami efektorowymi i powinowactwa połączonymi trifunkcyjnym reagentem
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
AU2004213752B2 (en) * 2003-01-31 2008-10-23 Immunomedics, Inc. Methods and compositions for administering therapeutic and diagnostic agents
US7259249B2 (en) * 2003-12-01 2007-08-21 Immunomedics, Inc. Method for preparing conjugates of proteins and chelating agents
RS54088B1 (en) * 2005-07-25 2015-10-30 Emergent Products Development Seattle Llc B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
PE20120259A1 (es) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37

Also Published As

Publication number Publication date
CN104338154A (zh) 2015-02-11
CN102762230A (zh) 2012-10-31
KR20170084349A (ko) 2017-07-19
JP2015057415A (ja) 2015-03-26
US8628749B2 (en) 2014-01-14
IL237507A0 (en) 2015-04-30
DK2528627T3 (da) 2014-05-12
RU2664475C1 (ru) 2018-08-17
SG182685A1 (en) 2012-08-30
CA2786655A1 (en) 2011-08-04
EP2528627A2 (en) 2012-12-05
RU2560587C9 (ru) 2015-11-27
NO20100143A1 (no) 2011-08-01
KR101758409B1 (ko) 2017-07-14
BR112012018843A2 (pt) 2017-10-17
ZA201205007B (en) 2013-09-25
AU2011209441B2 (en) 2016-03-03
BR112012018843B1 (pt) 2020-09-24
KR101893720B1 (ko) 2018-08-30
JP5855209B2 (ja) 2016-02-09
RU2012135430A (ru) 2014-03-10
EP2705857B1 (en) 2016-06-22
JP5646652B2 (ja) 2014-12-24
EP2528627B1 (en) 2014-03-19
PH12017501038B1 (en) 2017-12-11
SI2528627T1 (sl) 2014-08-29
US20120301396A1 (en) 2012-11-29
CA2786655C (en) 2016-12-13
IL221091A0 (en) 2012-09-24
WO2011092295A2 (en) 2011-08-04
ES2592402T3 (es) 2016-11-30
CN102762230B (zh) 2014-08-13
KR20130028051A (ko) 2013-03-18
MX342539B (es) 2016-10-04
EP2705857A3 (en) 2014-07-30
PT2528627E (pt) 2014-06-12
BR112012018843A8 (pt) 2017-12-19
AU2011209441A1 (en) 2012-07-19
DK2705857T3 (en) 2016-08-29
US9358309B2 (en) 2016-06-07
NO331080B1 (no) 2011-09-26
IL221091A (en) 2015-03-31
BR112012018843B8 (pt) 2020-12-22
HRP20140538T1 (hr) 2014-07-18
HK1195736A1 (zh) 2014-11-21
US20140147384A1 (en) 2014-05-29
EP2705857A2 (en) 2014-03-12
MX2012008695A (es) 2012-11-23
ES2469140T3 (es) 2014-06-17
NZ601055A (en) 2013-12-20
RU2560587C2 (ru) 2015-08-20
UA108631C2 (xx) 2015-05-25
PL2528627T3 (pl) 2014-08-29
WO2011092295A3 (en) 2011-11-24
CN104338154B (zh) 2017-09-22
RS53346B (en) 2014-10-31
JP2013518086A (ja) 2013-05-20
PH12017501038A1 (en) 2017-12-11

Similar Documents

Publication Publication Date Title
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
HK1206004A1 (zh) 巨大戟二萜醇- -酰化物 和巨大戟二萜醇- -氨基甲酸酯
HK1187049A1 (zh) 雙芳基連接的芳基三唑酮及其用途
IL237507A0 (en) Radioimmunoconjugates and their uses
EP2552953A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
HRP20160922T1 (hr) Oligopeptidni spojevi i njihove uporabe
HRP20182083T1 (hr) Nova kombinacija i uporaba
AP2013006947A0 (en) Compounds and their use
EP2608785A4 (en) LIPOMA CYCLES AND ITS USES
EP2529013A4 (en) NOVEL BETA GLUCOSIDASE AND USES THEREOF
EP2615094A4 (en) SESTERTERPEN COMPOUNDS AND THEIR USE
EP2638160A4 (en) NUCLIONS AND RIBOCAPSIDES
GB201014319D0 (en) Compounds and uses thereof
GB201020268D0 (en) Composition and uses
EP2567956A4 (en) NEW PRENYLAR CONNECTION AND USE THEREOF

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230201